www mnl777 com promotion

www mnl777 com promotion Former Barcelona and Uruguay striker Luis Suarez has signed a one-year contract extension with the Major League Soccer club and will line up under new coach Javier Mascherano next season, the club said. The 37-year-old striker has scored 25 goals in all competitions since joining the club before the start of this season including 20 in Miami's record-breaking regular season campaign. After winning the Supporters' Shield for the best record in the regular season, with a new points tally record, Miami were eliminated from the playoffs in the first round by Atlanta United. Since then Argentina head coach Gerardo Martino has left the club with his compatriot and Suarez's former team-mate at Barca, Mascherano appointed on Tuesday. "I'm very happy, very excited to continue for another year and to be able to enjoy being here with this fan base, which for us is like family. We feel very, very connected with them, and hopefully, next year, we can bring them even more joy," said Suarez. Miami's president of football operations Raul Sanllehi said Suarez had shown he remains an elite level forward but was also a key component in the dressing room. "Luis was not only our leading scorer this season, but also a leader for the group. His impact cannot be understated," he said. Suarez announced in September he was retiring from international duty with the Uruguay national team after scoring 69 goals in 143 games. The forward played in Europe for Ajax, Liverpool and Atletico Madrid and had a season in Brazil with Gremio before joining Miami. sev/mw

FLORENCE, Italy & BARCELONA, Spain--(BUSINESS WIRE)--Dec 11, 2024-- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, along with MEDSIR, a leading global independent clinical research company in oncology and part of Oncoclínicas & Co., the largest specialized oncology treatment group in Latin America, presented research on the pioneering clinical trial ADELA. This important research addresses therapeutic resistance in advanced ER+/HER2- breast cancer. Presented at the San Antonio Breast Cancer Symposium 2024 (SABCS), the study represents a key milestone in the quest for more effective and personalized treatment options for patients with disease progression. The standard first-line treatment for advanced ER+/HER2- breast cancer combines endocrine therapy with CDK4/6 inhibitors. mutations develop as a result of prior exposure to endocrine therapy during metastatic treatment, and up to 50% of ER+, HER2- advanced or metastatic breast cancers will develop these mutations. mutations cause the tumors to become resistant to endocrine therapy, in turn causing the cancer to progress; therefore, it is important to test for whenever mBC progresses. Longer exposure to endocrine therapy during first-line treatment increases the chance of a patient’s tumor developing an mutation. With the goal of addressing this unmet medical need, the ADELA phase III clinical trial investigates a new therapeutic option combining elacestrant, a next generation, oral selective estrogen receptor degrader, with everolimus, an mTORC1 inhibitor. This combination is being evaluated in patients with advanced ER+/HER2- breast cancer that harbors mutations, and who have experienced progression after standard first-line treatment. Results from the phase III EMERALD study were the basis for elacestrant’s approval. Meanwhile, everolimus has shown efficacy in inhibiting other resistance mechanisms in this type of cancer. The elacestrant and everolimus combination has demonstrated preliminary efficacy with a manageable safety profile in the phase 1b/2 ELEVATE study ( ). “We at Menarini Stemline are delighted to announce the collaboration with MEDSIR to continue advancing the clinical research to explore the combination therapy with elacestrant,” said Nassir Habboubi, MD, Chief Medical Officer of Stemline Therapeutics. “We are committed to driving innovation in cancer treatment by delivering transformational therapies aiming to extend the lives of people living with cancer.” The primary objective of this international, randomized, double-blind trial is to evaluate whether the combination of elacestrant and everolimus offers greater efficacy in delaying disease progression compared to elacestrant monotherapy. Additionally, it investigates other crucial aspects, such as overall survival, toxicity profile, and the impact on patients’ quality of life. The ADELA study represents a critical step in understanding how to overcome tumor resistance challenges in patients with mutations, with the goal of advancing towards more effective and safer treatments. “At MEDSIR, we understand innovation not only as achieving clinical results but as the ability to transform patients' lives on a global scale. With ADELA, we take a decisive step toward accomplishing less invasive and more accessible treatments, aiming to offer new hope to those facing the most complex forms of the disease. This advancement reinforces our commitment to increasingly personalized and patient-centered medicine, a fundamental pillar in shaping the future of oncology,” said Dr. Antonio Llombart-Cussac, Senior Scientific Leader at MEDSIR. The phase III study not only has significant clinical objectives, but also holds the potential to pave the way for regulatory approval of this therapeutic combination, enabling its use in a broader population of patients with advanced breast cancer. Moreover, the international scope of the study, which includes participation from multiple countries, including Spain, Italy, France, Austria, the Czech Republic, Greece, Germany, and the United Kingdom, underscores the study’s global importance and relevance in the scientific community. The presentation of the ADELA study at an event as prominent as SABCS 2024 reinforces MEDSIR’s leadership in excellence-driven oncology research and highlights its focus on addressing unmet needs in breast cancer treatment. The ADELA study is active and already recruiting patients. ORSERDU (elacestrant), 345 mg tablets, is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Full prescribing information for the U.S. can be found at . : Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively. Monitor lipid profile prior to starting and periodically while taking ORSERDU. : Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the final dose. occurred in 12% of patients who received ORSERDU. Serious adverse reactions in >1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each). , including laboratory abnormalities, of ORSERDU were musculoskeletal pain (41%), nausea (35%), increased cholesterol (30%), increased AST (29%), increased triglycerides (27%), fatigue (26%), decreased hemoglobin (26%), vomiting (19%), increased ALT (17%), decreased sodium (16%), increased creatinine (16%), decreased appetite(15%), diarrhea(13%), headache (12%), constipation (12%), abdominal pain (11%), hot flush (11%), and dyspepsia (10%). : Avoid concomitant use of strong or moderate CYP3A4 inhibitors with ORSERDU. Avoid concomitant use of strong or moderate CYP3A4 inducers with ORSERDU. : Advise lactating women to not breastfeed during treatment with ORSERDU and for 1 week after the last dose. : Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of ORSERDU in patients with moderate hepatic impairment (Child-Pugh B). The safety and effectiveness of ORSERDU in pediatric patients have not been established. To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or FDA at 1-800-FDA-1088 or . The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $4.7 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide. For further information, please visit . Stemline Therapeutics, Inc. (“Stemline”) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes ORSERDU ® (elacestrant) in the U.S. and Europe, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline also commercializes ELZONRIS ® (tagraxofusp-erzs), a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States and Europe, which is the only approved treatment for BPDCN in the U.S. and E.U. to date. Stemline also commercializes NEXPOVIO ® (selinexor) in Europe, an XPO1 inhibitor for multiple myeloma. Stemline also has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers. Established in 2012, MEDSIR prides itself on working closely with its strategic partners to drive innovation in oncology research. Operating in Spain and the United States, the company provides end-to-end clinical trial management, from study design to publication, with an extensive global network of experts and integrated technology to streamline the process. The company offers proof-of-concept support and a strategic approach that enables research partners to benefit from the best of both worlds: industry clinical research and investigator-driven trials. With the aim of promoting independent research worldwide, MEDSIR has formed a strategic alliance with Oncoclínicas, the leading oncology group in Brazil, which offers outstanding research potential in South America. For further information: Oncoclínicas&Co is the largest group dedicated to cancer treatment in Latin America, with a specialized and innovative model focused on the entire oncology care journey, combining operational efficiency, humanized care, and high specialization through a medical team composed of over 2,700 specialist physicians with an emphasis on oncology. With its mission to democratize cancer treatment, it offers a comprehensive system that integrates outpatient clinics with high-complexity cancer centers. The company operates 145 units across 39 Brazilian cities, allowing high-quality access in all regions it serves, aligned with world-class standards. Focusing on technology, precision medicine, and genomics, Oncoclínicas performed approximately 635,000 treatments in 2023. It is the exclusive partner in Brazil of the Dana Farber Cancer Institute, affiliated with Harvard Medical School, one of the world’s leading cancer research and treatments centers. The company also owns Boston Lighthouse Innovation, a bioinformatics firm based in Cambridge, United States, and holds shares in Medsir, a company dedicated to the development and management of clinical trials for independent cancer research, based in Barcelona, Spain. Recently, Oncoclínicas expanded its operations to Saudi Arabia through a joint venture with the Al Faisaliah Group, bringing its mission to beat cancer to a new continent and providing advanced oncology care on a global scale by combining oncological hyperspecialization with innovative treatment approaches. The company is part of the IDIVERSA index, launched by B3, highlighting companies committed to gender and racial diversity. For more information, visit: . View source version on : CONTACT: Media Contacts The Menarini Group Valeria Speroni Cardi Email:pressoffice@menarini.comStemline Therapeutics, Inc. Cheya Pope Email:media@menarinistemline.comGlobal Brand Communication MEDSIR: Sergio Aguilar Global Brand & Communication Director +34 674 82 87 24 Martín Espallargas Global Communication & Marketing Manager +34 634 835 389 Berloso Cortés International PR & Comms +34 677 49 75 23 KEYWORD: TEXAS SPAIN NORTH AMERICA UNITED STATES EUROPE ITALY INDUSTRY KEYWORD: RESEARCH CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE ONCOLOGY SOURCE: The Menarini Group Copyright Business Wire 2024. PUB: 12/11/2024 06:35 PM/DISC: 12/11/2024 06:35 PMOregon 78, San Diego St. 68Raiders great denies intimidating police, set to fight charges in hearing

FLORENCE, Italy & BARCELONA, Spain--(BUSINESS WIRE)--Dec 11, 2024-- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, along with MEDSIR, a leading global independent clinical research company in oncology and part of Oncoclínicas & Co., the largest specialized oncology treatment group in Latin America, presented research on the pioneering clinical trial ADELA. This important research addresses therapeutic resistance in advanced ER+/HER2- breast cancer. Presented at the San Antonio Breast Cancer Symposium 2024 (SABCS), the study represents a key milestone in the quest for more effective and personalized treatment options for patients with disease progression. The standard first-line treatment for advanced ER+/HER2- breast cancer combines endocrine therapy with CDK4/6 inhibitors. mutations develop as a result of prior exposure to endocrine therapy during metastatic treatment, and up to 50% of ER+, HER2- advanced or metastatic breast cancers will develop these mutations. mutations cause the tumors to become resistant to endocrine therapy, in turn causing the cancer to progress; therefore, it is important to test for whenever mBC progresses. Longer exposure to endocrine therapy during first-line treatment increases the chance of a patient’s tumor developing an mutation. With the goal of addressing this unmet medical need, the ADELA phase III clinical trial investigates a new therapeutic option combining elacestrant, a next generation, oral selective estrogen receptor degrader, with everolimus, an mTORC1 inhibitor. This combination is being evaluated in patients with advanced ER+/HER2- breast cancer that harbors mutations, and who have experienced progression after standard first-line treatment. Results from the phase III EMERALD study were the basis for elacestrant’s approval. Meanwhile, everolimus has shown efficacy in inhibiting other resistance mechanisms in this type of cancer. The elacestrant and everolimus combination has demonstrated preliminary efficacy with a manageable safety profile in the phase 1b/2 ELEVATE study ( ). “We at Menarini Stemline are delighted to announce the collaboration with MEDSIR to continue advancing the clinical research to explore the combination therapy with elacestrant,” said Nassir Habboubi, MD, Chief Medical Officer of Stemline Therapeutics. “We are committed to driving innovation in cancer treatment by delivering transformational therapies aiming to extend the lives of people living with cancer.” The primary objective of this international, randomized, double-blind trial is to evaluate whether the combination of elacestrant and everolimus offers greater efficacy in delaying disease progression compared to elacestrant monotherapy. Additionally, it investigates other crucial aspects, such as overall survival, toxicity profile, and the impact on patients’ quality of life. The ADELA study represents a critical step in understanding how to overcome tumor resistance challenges in patients with mutations, with the goal of advancing towards more effective and safer treatments. “At MEDSIR, we understand innovation not only as achieving clinical results but as the ability to transform patients' lives on a global scale. With ADELA, we take a decisive step toward accomplishing less invasive and more accessible treatments, aiming to offer new hope to those facing the most complex forms of the disease. This advancement reinforces our commitment to increasingly personalized and patient-centered medicine, a fundamental pillar in shaping the future of oncology,” said Dr. Antonio Llombart-Cussac, Senior Scientific Leader at MEDSIR. The phase III study not only has significant clinical objectives, but also holds the potential to pave the way for regulatory approval of this therapeutic combination, enabling its use in a broader population of patients with advanced breast cancer. Moreover, the international scope of the study, which includes participation from multiple countries, including Spain, Italy, France, Austria, the Czech Republic, Greece, Germany, and the United Kingdom, underscores the study’s global importance and relevance in the scientific community. The presentation of the ADELA study at an event as prominent as SABCS 2024 reinforces MEDSIR’s leadership in excellence-driven oncology research and highlights its focus on addressing unmet needs in breast cancer treatment. The ADELA study is active and already recruiting patients. ORSERDU (elacestrant), 345 mg tablets, is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Full prescribing information for the U.S. can be found at . : Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively. Monitor lipid profile prior to starting and periodically while taking ORSERDU. : Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the final dose. occurred in 12% of patients who received ORSERDU. Serious adverse reactions in >1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each). , including laboratory abnormalities, of ORSERDU were musculoskeletal pain (41%), nausea (35%), increased cholesterol (30%), increased AST (29%), increased triglycerides (27%), fatigue (26%), decreased hemoglobin (26%), vomiting (19%), increased ALT (17%), decreased sodium (16%), increased creatinine (16%), decreased appetite(15%), diarrhea(13%), headache (12%), constipation (12%), abdominal pain (11%), hot flush (11%), and dyspepsia (10%). : Avoid concomitant use of strong or moderate CYP3A4 inhibitors with ORSERDU. Avoid concomitant use of strong or moderate CYP3A4 inducers with ORSERDU. : Advise lactating women to not breastfeed during treatment with ORSERDU and for 1 week after the last dose. : Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of ORSERDU in patients with moderate hepatic impairment (Child-Pugh B). The safety and effectiveness of ORSERDU in pediatric patients have not been established. To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or FDA at 1-800-FDA-1088 or . The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $4.7 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide. For further information, please visit . Stemline Therapeutics, Inc. (“Stemline”) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes ORSERDU ® (elacestrant) in the U.S. and Europe, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline also commercializes ELZONRIS ® (tagraxofusp-erzs), a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States and Europe, which is the only approved treatment for BPDCN in the U.S. and E.U. to date. Stemline also commercializes NEXPOVIO ® (selinexor) in Europe, an XPO1 inhibitor for multiple myeloma. Stemline also has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers. Established in 2012, MEDSIR prides itself on working closely with its strategic partners to drive innovation in oncology research. Operating in Spain and the United States, the company provides end-to-end clinical trial management, from study design to publication, with an extensive global network of experts and integrated technology to streamline the process. The company offers proof-of-concept support and a strategic approach that enables research partners to benefit from the best of both worlds: industry clinical research and investigator-driven trials. With the aim of promoting independent research worldwide, MEDSIR has formed a strategic alliance with Oncoclínicas, the leading oncology group in Brazil, which offers outstanding research potential in South America. For further information: Oncoclínicas&Co is the largest group dedicated to cancer treatment in Latin America, with a specialized and innovative model focused on the entire oncology care journey, combining operational efficiency, humanized care, and high specialization through a medical team composed of over 2,700 specialist physicians with an emphasis on oncology. With its mission to democratize cancer treatment, it offers a comprehensive system that integrates outpatient clinics with high-complexity cancer centers. The company operates 145 units across 39 Brazilian cities, allowing high-quality access in all regions it serves, aligned with world-class standards. Focusing on technology, precision medicine, and genomics, Oncoclínicas performed approximately 635,000 treatments in 2023. It is the exclusive partner in Brazil of the Dana Farber Cancer Institute, affiliated with Harvard Medical School, one of the world’s leading cancer research and treatments centers. The company also owns Boston Lighthouse Innovation, a bioinformatics firm based in Cambridge, United States, and holds shares in Medsir, a company dedicated to the development and management of clinical trials for independent cancer research, based in Barcelona, Spain. Recently, Oncoclínicas expanded its operations to Saudi Arabia through a joint venture with the Al Faisaliah Group, bringing its mission to beat cancer to a new continent and providing advanced oncology care on a global scale by combining oncological hyperspecialization with innovative treatment approaches. The company is part of the IDIVERSA index, launched by B3, highlighting companies committed to gender and racial diversity. For more information, visit: . View source version on : CONTACT: Media Contacts The Menarini Group Valeria Speroni Cardi Email:pressoffice@menarini.comStemline Therapeutics, Inc. Cheya Pope Email:media@menarinistemline.comGlobal Brand Communication MEDSIR: Sergio Aguilar Global Brand & Communication Director +34 674 82 87 24 Martín Espallargas Global Communication & Marketing Manager +34 634 835 389 Berloso Cortés International PR & Comms +34 677 49 75 23 KEYWORD: TEXAS SPAIN NORTH AMERICA UNITED STATES EUROPE ITALY INDUSTRY KEYWORD: RESEARCH CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE ONCOLOGY SOURCE: The Menarini Group Copyright Business Wire 2024. PUB: 12/11/2024 06:35 PM/DISC: 12/11/2024 06:35 PMHere's what to know about the new funding deal that countries agreed to at UN climate talks

Boise State withdraws from Mountain West volleyball tournament rather than play San Jose StateVysion Technology Solutions Launches 2024 Holiday Hat, Coat, and Gloves Drive

AMMO, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 29, 2024 Deadline to file Lead Plaintiff MotionThe large mysterious drones reported flying over parts of New Jersey in recent weeks appear to avoid detection by traditional methods such as helicopter and radio, according to a state lawmaker briefed Wednesday by the Department of Homeland Security. In a post on the social media platform X, Assemblywoman Dawn Fantasia described the drones as up to 6 feet in diameter and sometimes traveling with their lights switched off. The Morris County Republican was among several state and local lawmakers who met with state police and Homeland Security officials to discuss the spate of sightings that range from the New York City area through New Jersey and westward into parts of Pennsylvania, including over Philadelphia. The devices do not appear to be The dronees wereffffflown by hobbyists, Fantasia wrote. Dozens of mysterious nighttime flights started last month and have raised growing concern among residents and officials. Part of the worry stems from the flying objects initially being spotted near the Picatinny Arsenal, a U.S. military research and manufacturing facility; and over President-elect Donald Trump’s golf course in Bedminster. Drones are legal in New Jersey for recreational and commercial use, but they are subject to local and Federal Aviation Administration regulations and flight restrictions. Operators must be FAA certified. Most, but not all, of the drones spotted in New Jersey were larger than those typically used by hobbyists. The number of sightings has increased in recent days, though officials say many of the objects seen may have been planes rather than drones. It’s also possible that a single drone has been reported more than once. Gov. Phil Murphy and law enforcement officials have stressed that the drones don’t appear to threaten public safety. The FBI has been investigating and has asked residents to share any videos, photos or other information they may have. Two Republican Jersey Shore-area congressmen, U.S. Reps. Chris Smith and Jeff Van Drew, have called on the military to shoot down the drones. Smith said a Coast Guard commanding officer briefed him on an incident over the weekend in which a dozen drones followed a motorized Coast Guard lifeboat “in close pursuit” near Barnegat Light and Island Beach State Park in Ocean County. Coast Guard Lt. Luke Pinneo told The Associated Press Wednesday “that multiple low-altitude aircraft were observed in vicinity of one of our vessels near Island Beach State Park.” The aircraft weren't perceived as an immediate threat and didn't disrupt operations, Pinneo said. The Coast Guard is assisting the FBI and state agencies in investigating. In a letter to U.S. Defense Secretary Lloyd Austin, Smith called for military help dealing with the drones, noting that Joint Base McGuire-Dix-Lakehurst has the capability "to identify and take down unauthorized unmanned aerial systems.” However, Pentagon spokeswoman Sabrina Singh told reporters Wednesday that “our initial assessment here is that these are not drones or activities coming from a foreign entity or adversary.” Many municipal lawmakers have called for more restrictions on who is entitled to fly the unmanned devices. At least one state lawmaker proposed a temporary ban on drone flights in the state. “This is something we’re taking deadly seriously. I don’t blame people for being frustrated," Murphy said earlier this week. A spokesman for the Democratic governor said he did not attend Wednesday's meeting. Republican Assemblyman Erik Peterson, whose district includes parts of the state where the drones have been reported, said he also attended Wednesday's meeting at a state police facility in West Trenton. The session lasted for about 90 minutes. Peterson said DHS officials were generous with their time, but appeared dismissive of some concerns, saying not all the sightings reported have been confirmed to involve drones. So who or what is behind the flying objects? Where are they coming from? What are they doing? “My understanding is they have no clue,” Peterson said. A message seeking comment was left with the Department of Homeland Security. Most of the drones have been spotted along coastal areas and some were recently reported flying over a large reservoir in Clinton. Sightings also have been reported in neighboring states. James Edwards, of Succasunna, New Jersey, said he has seen a few drones flying over his neighborhood since last month. “It raises concern mainly because there's so much that's unknown,” Edwards said Wednesday. “There are lots of people spouting off about various conspiracies that they believe are in play here, but that only adds fuel to the fire unnecessarily. We need to wait and see what is really happening here, not let fear of the unknown overtake us." —— AP reporters Mike Catalini in Morrisville, Pennsylvania; and Wayne Parry in Point Pleasant, New Jersey, contributed to this report.

KENNESAW, Ga. (AP) — Adrian Wooley and Simeon Cottle each scored 32 points and Kennesaw State beat Brewton-Parker 112-77 on Sunday. Wooley added eight rebounds and eight assists for the Owls (8-5). Cottle went 11 of 16 from the field (8 for 13 from 3-point range) to add 32 points. Braedan Lue went 5 of 8 from the field (2 for 3 from 3-point range) to finish with 14 points. Dre Burroughs finished with 25 points for the Barons. Brewton-Parker got 20 points and seven rebounds from Tommy J Tisdale III. Kennesaw State took the lead with 15:42 left in the first half and did not give it up. The score was 57-31 at halftime, with Cottle racking up 16 points. Kennesaw State extended its lead to 83-38 during the second half, fueled by a 10-0 scoring run. Wooley scored a team-high 19 points in the second half as their team closed out the win. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Adam Gault/OJO Images via Getty Images The Eaton Vance Tax-Managed Diversified Equity Income Fund ( NYSE: ETY ) is a closed-end fund that income-focused investors may wish to purchase as a means of generating income from the assets that they already At Energy Profits in Dividends, we seek to generate a 7%+ income yield by investing in a portfolio of energy stocks while minimizing our risk of principal loss. By subscribing, you will get access to our best ideas earlier than they are released to the general public (and many of them are not released at all) as well as far more in-depth research than we make available to everybody. In addition, all subscribers can read any of my work without a subscription to Seeking Alpha Premium! We are currently offering a two-week free trial for the service, so check us out ! Power Hedge has been covering both traditional and renewable energy since 2010. He targets primarily international companies of all sizes that hold a competitive advantage and pay dividends with strong yields. Energy Profits in Dividends Learn more Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK (AP) — A number of President-elect Donald Trump 's most prominent Cabinet picks and appointees have been targeted by bomb threats and “swatting attacks," Trump's transition team said Wednesday. The FBI said it was investigating. “Last night and this morning, several of President Trump’s Cabinet nominees and Administration appointees were targeted in violent, unAmerican threats to their lives and those who live with them," Trump transition spokesperson Karoline Leavitt said in a statement. She said the attacks ranged from bomb threats to swatting, in which attackers initiate an emergency law enforcement response against a target victim under false pretenses. The tactic has become a popular one in recent years. Leavitt said law enforcement and other authorities acted quickly to ensure the safety of those who were targeted and Trump and his transition team are grateful. Among those targeted were New York Rep. Elise Stefanik, Trump’s pick to serve as the next ambassador to the United Nations ; Matt Gaetz, Trump’s initial pick to serve as attorney general ; and former New York congressman Lee Zeldin, who has been tapped to lead the Environmental Protection Agency. Law enforcement officials are also looking into whether Susie Wiles, Trump’s incoming chief of staff, and Pam Bondi, the former Florida attorney general whom Trump has chosen as Gaetz’s replacement, and other incoming administration officials were also victims — as well as how each was targeted, according to a law enforcement official who spoke on condition of anonymity as the investigation continues. Wiles and Bondi did not immediately respond to requests for comment. The FBI said in a statement that it was “aware of numerous bomb threats and swatting incidents targeting incoming administration nominees and appointees" and was investigating with its law enforcement partners. The FBI added: "We take all potential threats seriously, and as always, encourage members of the public to immediately report anything they consider suspicious to law enforcement.” White House spokesperson Saloni Sharma said President Joe Biden had been briefed and the White House is in touch with federal law enforcement and Trump's transition team. Biden “continues to monitor the situation closely," Sharma said, adding the president and his administration “condemn threats of political violence.” Stefanik's office said that, on Wednesday morning, she, her husband, and their 3-year-old son were driving home from Washington for Thanksgiving when they were informed of a bomb threat to their residence in Saratoga County. Her office said “New York State, County law enforcement, and U.S. Capitol Police responded immediately with the highest levels of professionalism.” The New York State Police said a team was dispatched to sweep Stefanik’s home on Wednesday morning in response to the bomb threat but did not locate any explosive devices. The agency directed further questions to the FBI. Zeldin said in a social media post that he and his family had been threatened. “A pipe bomb threat targeting me and my family at our home today was sent in with a pro-Palestinian themed message,” he wrote on X . “My family and I were not home at the time and are safe. We are working with law enforcement to learn more as this situation develops.” Police in Suffolk County, Long Island, said emergency officers responded to a bomb threat Wednesday morning at an address listed in public records as Zeldin’s home and were checking the property. In Florida, the Okaloosa County sheriff’s office said on Facebook that it “received notification of a bomb threat referencing former Congressman Matt Gaetz’s supposed mailbox at a home in the Niceville area" around 9 a.m. Wednesday. While a family member resides at the address, the office said, Gaetz “is NOT a resident.” No threatening devices were found. Gaetz was Trump’s initial pick to serve as attorney general, but he withdrew from consideration after allegations that he paid women for sex and slept with underage women. Gaetz has vehemently denied any wrongdoing and said last year that a Justice Department investigation into sex trafficking allegations involving underage girls had ended with no federal charges against him. The threats follow a political campaign marked by disturbing and unprecedented violence. In July, a gunman opened fire at a Trump rally in Butler, Pennsylvania, grazing the then-candidate in the ear with a bullet and killing one of his supporters. The Secret Service later thwarted a subsequent assassination attempt at Trump's West Palm Beach, Florida, golf course when an agent spotted the barrel of a gun poking through a perimeter fence while Trump was golfing. Trump was also the subject of an Iranian murder-for-hire plot , with a man saying he had been tasked with planning the assassination of the Republican president-elect. Also this week, authorities arrested a man they say posted videos on social media threatening to kill Trump, according to court documents. In one video posted on Nov. 13, Manuel Tamayo-Torres threatened to shoot the former president while holding what appeared to be an AR-15 style rifle, authorities said Among the other videos he posted was one from an arena in Glendale, Arizona on Aug. 23, the same day Trump held a campaign rally there, according to court papers. An attorney for Tamayo-Torres did not immediately respond to a request for comment Wednesday. Public figures across the political spectrum have been targeted in recent years by hoax bomb threats and false reports of shootings at their homes. About a year ago the FBI responded to an uptick in such incidents at the homes of public officials, state capitols and courthouses across the country around the holidays. Many were locked down and evacuated in early January after receiving bomb threats. No explosives were found and no one was hurt. Some of those targeted last year were Georgia Lt. Gov. Burt Jones, Boston Mayor Michelle Wu and Ohio Attorney General Dave Yost. In Wu’s case, a male caller told police he had shot his own wife and tied another man up. When police and EMT responders arrived at the address given by the caller, they quickly realized it was the Boston mayor’s home. Wu, a Democrat, has also been targeted by many swatting calls since she took office in 2021. The judges overseeing the civil fraud case against Trump in New York and the criminal election interference case against him in Washington were both targeted earlier this year. Justice Department special counsel Jack Smith, who recently abandoned the two criminal cases he brought against Trump, was also the subject of a fake emergency call on Christmas Day last year. Earlier this year, schools, government buildings and the homes of city officials in Springfield, Ohio, received a string of hoax bomb threats after Trump falsely accused members of Springfield’s Haitian community of abducting and eating cats and dogs. And in 2022, a slew of historically Black colleges and universities nationwide were targeted with dozens of bomb threats, with the vast majority arriving during the celebration of Black History Month. The U.S. Capitol Police said in a statement Wednesday that anytime a member of Congress is the victim of a swatting' incident, “we work closely with our local and federal law enforcement partners.” The force declined to provide further details, in part to “minimize the risk of copy-cats.” Republican House Speaker Mike Johnson called the threats “dangerous and unhinged.” “This year, there was not just one but TWO assassination attempts on President Trump," he wrote on X . “Now some of his Cabinet nominees and their families are facing bomb threats.” He added: “It is not who we are in America.” ___ Richer reported from Washington. Associated Press writers Colleen Long and Eric Tucker in Washington, Scott Bauer in Madison, Wisconsin, and Anthony Izaguirre in Albany, New York, contributed to this report.Wall Street gets back to climbing, Nasdaq tops 20,000

Chimezie's late layup lifts Boston University past Maine 59-56Better AI Stock: Nvidia vs. Palantir?

NEW YORK (AP) — A number of President-elect Donald Trump 's most prominent Cabinet picks and appointees have been targeted by bomb threats and “swatting attacks," Trump's transition team said Wednesday. The FBI said it was investigating. “Last night and this morning, several of President Trump’s Cabinet nominees and Administration appointees were targeted in violent, unAmerican threats to their lives and those who live with them," Trump transition spokesperson Karoline Leavitt said in a statement. The attacks ranged from bomb threats to swatting, in which attackers initiate an emergency law enforcement response against a target victim under false pretenses, she said. The tactic has become a popular one in recent years. Leavitt said law enforcement and other authorities acted quickly to ensure the safety of those who were targeted and Trump and his transition team are grateful. Among those targeted were New York Rep. Elise Stefanik, Trump’s pick to serve as the next ambassador to the United Nations ; Matt Gaetz, Trump’s initial pick to serve as attorney general ; Oregon Rep. Lori Chavez-DeRemer, whom Trump chose to lead the Department of Labor , and former New York congressman Lee Zeldin, who has been tapped to lead the Environmental Protection Agency. Law enforcement officials are also looking into whether Susie Wiles, Trump’s incoming chief of staff, and Pam Bondi, the former Florida attorney general whom Trump has chosen as Gaetz’s replacement, and other incoming administration officials were also victims — as well as how each was targeted, according to a law enforcement official who spoke on condition of anonymity as the investigation continues. Wiles and Bondi did not immediately respond to requests for comment. The FBI said in a statement that it was “aware of numerous bomb threats and swatting incidents targeting incoming administration nominees and appointees" and was investigating with its law enforcement partners. White House spokesperson Saloni Sharma said President Joe Biden had been briefed and the White House is in touch with federal law enforcement and Trump's transition team. Biden “continues to monitor the situation closely," Sharma said, adding the president and his administration “condemn threats of political violence.” Stefanik's office said that, on Wednesday morning, she, her husband, and their 3-year-old son were driving home from Washington for Thanksgiving when they were informed of a bomb threat to their residence in Saratoga County. Police swept Stefanik’s home on Wednesday morning in response to the bomb threat but did not locate any explosive devices, New York State Police said. Zeldin said in a social media post that he and his family had also been threatened. “A pipe bomb threat targeting me and my family at our home today was sent in with a pro-Palestinian themed message,” he wrote on X . “My family and I were not home at the time and are safe." In Florida, the Okaloosa County sheriff’s office said on Facebook that it “received notification of a bomb threat referencing former Congressman Matt Gaetz’s supposed mailbox at a home in the Niceville area" Wednesday. While a family member resides at the address, the office said, Gaetz “is NOT a resident.” No threatening devices were found. Gaetz was Trump’s initial pick to serve as attorney general, but he withdrew from consideration after allegations that he paid women for sex and slept with underage women. Gaetz has vehemently denied any wrongdoing, and a Justice Department investigation into sex trafficking allegations ended with no charges against him. The threats follow a political campaign marked by disturbing and unprecedented violence. In July, a gunman opened fire at a Trump rally in Butler, Pennsylvania, grazing the then-candidate in the ear with a bullet and killing one of his supporters. The Secret Service later thwarted a subsequent assassination attempt at Trump's West Palm Beach, Florida, golf course when an agent spotted the barrel of a gun poking through a perimeter fence while Trump was golfing. Trump was also the subject of an Iranian murder-for-hire plot , with a man saying he had been tasked with planning the assassination of the Republican president-elect. Also this week, authorities arrested a man they say posted videos on social media threatening to kill Trump, according to court documents. In one video posted on Nov. 13, Manuel Tamayo-Torres threatened to shoot the former president while holding what appeared to be an AR-15 style rifle, authorities said Among the other videos he posted was one from an arena in Glendale, Arizona on Aug. 23, the same day Trump held a campaign rally there, according to court papers. An attorney for Tamayo-Torres did not immediately respond to a request for comment Wednesday. Public figures across the political spectrum have been targeted in recent years by hoax bomb threats and false reports of shootings at their homes. About a year ago the FBI responded to an uptick in such incidents at the homes of public officials, state capitols and courthouses across the country around the holidays. Many were locked down and evacuated in early January after receiving bomb threats. No explosives were found and no one was hurt. Some of those targeted last year were Georgia Lt. Gov. Burt Jones, Boston Mayor Michelle Wu and Ohio Attorney General Dave Yost. The judges overseeing the civil fraud case against Trump in New York and the criminal election interference case against him in Washington were both targeted earlier this year. Justice Department special counsel Jack Smith, who recently abandoned the two criminal cases he brought against Trump, was also the subject of a fake emergency call on Christmas Day last year. Earlier this year, schools, government buildings and the homes of city officials in Springfield, Ohio, received a string of hoax bomb threats after Trump falsely accused members of Springfield’s Haitian community of abducting and eating cats and dogs. And in 2022, a slew of historically Black colleges and universities nationwide were targeted with dozens of bomb threats, with the vast majority arriving during the celebration of Black History Month. The U.S. Capitol Police said in a statement Wednesday that anytime a member of Congress is the victim of a swatting' incident, “we work closely with our local and federal law enforcement partners.” The force declined to provide further details, in part to “minimize the risk of copy-cats.” Republican House Speaker Mike Johnson called the threats “dangerous and unhinged.” “This year, there was not just one but TWO assassination attempts on President Trump," he wrote on X . “Now some of his Cabinet nominees and their families are facing bomb threats.” He added: “It is not who we are in America.” ___ Richer reported from Washington. Associated Press writers Colleen Long and Eric Tucker in Washington, Scott Bauer in Madison, Wisconsin, and Anthony Izaguirre in Albany, New York, contributed to this report.Homeland Security shares new details of mysterious drone flights over New JerseyHappy Thanksgiving Eve, everyone. To some, Thanksgiving is the best holiday of the year. Who doesn't love food and football, after all? While there are of course some understandable criticisms of the holiday, given its origin and the treatment of Native Americans in this country, most seem to still enjoy it. However, in the wake of the 2024 presidential election, one prominent columnist is calling for Joe Biden to cancel the holiday. USA Today columnist Rex Huppke, a humor columnist for the prominent outlet, doesn't fee like celebrating the holiday this week. Kevin Sabitus/Getty Images The USA TODAY columnist published a piece on Wednesday titled, "Joe Biden Must Cancel Thanksgiving. MAGA And Non-MAGA Cannot Break Bread." The USA TODAY columnist believes that in the wake of the 2024 presidential election, the holiday should not go on. "In the wake of the presidential election," Huppke writes . "The last thing any of us need to be doing is walking into potentially volatile mixed-ideology settings that often feature alcohol, long-standing feelings of familial resentment and easily thrown pies." Wesley Hitt/Getty Images He believes that things could get heated at the table. "The social media posts I see from them, along with the regular MAGA missives I receive, are just as ornery as ever, He continued. "My ears are ringing from the loud and righteous calls that people like me need to ‘better understand Trump voters.’ But I can’t shake the fact that no Trump voter has ever been asked to understand me, or tried to for that matter." Adding: "Nobody’s telling them to spend time with a family who has a transgender child and understand the damage that comes from ignorant cruelty." While things could be a bit more heated this year, is it really any worse than in 2016 or '20? Honestly, it feels like people are more comfortable with where things are at. They might not like it, but the political climate does feel a bit tamed down, compared to where it was a couple of years ago. Of course, that could end up being a very wrong sentiment. We'll have to find out on Thanksgiving - as long as Biden doesn't cancel it!

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" Thanks for your interest in Kalkine Media's content! To continue reading, please log in to your account or create your free account with us.

Saudi Arabia and United States may Part ways over Security AgreementNone